Biomea Fusion, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BMEA, updated each market day.
BMEA AI Sentiment
AI sees no strong directional signal for Biomea Fusion, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Biomea Fusion, Inc. Common Stock
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Sector
Exchange
Market Cap
$133,753,964
Cap Tier
Employees
41
Headquarters
SAN CARLOS, CA
Listed Since
April 16, 2021
Website
BMEA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BMEA Volatility
Biomea Fusion, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
